Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same journal

Section: Book and Media.

Dimensions of critical care nursing : DCCN·2026

Same journal

Exploring RN Resignation Experiences.

Dimensions of critical care nursing : DCCN·2026

Same journal

Nursing Perspectives on Glycemic Control for Critically Ill Adults in the Intensive Care Unit: A Narrative Review.

Dimensions of critical care nursing : DCCN·2026

Same journal

Quantitative Pupillometry Values Are Similar in Bright Light and Dim Light Conditions.

Dimensions of critical care nursing : DCCN·2026

Same journal

Intravenous Smart Pump Alarms in Everyday Hospital Use: A Real-world Descriptive Analysis.

Dimensions of critical care nursing : DCCN·2026

Same journal

The Trajectories of Platelet, Fibrinogen, and D-dimer in Severe Trauma Patients and Their Value in Predicting Venous Thromboembolism: A Retrospective Study.

Dimensions of critical care nursing : DCCN·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

The use of beta-blockers to decrease adverse perioperative cardiac events.

Debora L Ryder¹

¹Postanesthesia Care Unit, Morton Plant North Bay Hospital, USA. Debora.ryder@baycare.org

Dimensions of Critical Care Nursing : DCCN

|May 31, 2008

Summary

Elderly patients undergoing surgery face high risks of myocardial ischemia, a serious cardiac complication. Underused beta-blockers could reduce this risk, necessitating a multidisciplinary approach for perioperative cardiac care.

Related Experiment Videos

Last Updated: Jul 4, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Area of Science:

Geriatric Medicine
Cardiology
Anesthesiology

Background:

Aging populations lead to increased surgeries in high-risk individuals.
Perioperative myocardial ischemia presents a significant mortality risk (70%) in surgical patients.
Complex patient factors include atypical presentations, pain, and analgesic effects.

Purpose of the Study:

To highlight the critical role of critical care nurses in managing perioperative risks.
To emphasize the underutilization of beta-blockers in preventing myocardial ischemia.
To advocate for a multidisciplinary strategy for optimal beta-blocker use in elderly surgical patients.

Main Methods:

Review of perioperative patient complexity and risk factors.
Analysis of myocardial ischemia incidence and mortality.
Assessment of beta-blocker efficacy and current usage patterns.

Main Results:

Myocardial ischemia is a major cause of perioperative complications and mortality.
Beta-blockers show potential in reducing myocardial ischemia risk.
Current use of beta-blockers in this population is suboptimal.

Conclusions:

A multidisciplinary approach is essential for effective perioperative cardiac risk management.
Optimizing beta-blocker therapy can mitigate cardiac complications in elderly surgical patients.
Improved nursing assessment and intervention are crucial for patient safety.